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FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
And Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterTASC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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SUMMARY 
 
Ischaemic heart disease is the most common cause of death in the UK and angina is a 
major cause of morbidity. Most patients with angina respond adequately to treatment with 
medication, angioplasty or bypass grafting. Some patients, however, present with angina 
that is refractory to such treatments. Transmyocardial laser revascularisation (TMLR) uses 
laser ablation to create transmural channels in the ischaemic myocardium and, thus, offers 
a new treatment to patients for whom medication or surgery has not been successful. 
 
There have been few published studies of TMLR. What studies there have been have 
demonstrated short-term benefit in terms of relief of angina, reduction in hospital admissions 
for angina, and reduction in the use of cardioactive medications; there is conflicting evidence 
regarding changes in myocardial perfusion or exercise capacity; there is no improvement in 
12 month survival. No studies with long-term follow-up have been published. There is little 
published data concerning cost-effectiveness: the cost per QALY is estimated to be at least 
£45,000. 
 
More evidence is required to demonstrate longer-term benefits, and to evaluate cost-
effectiveness. TMLR should continue to be offered to patients, but only within the context of 
clinical trials. 
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ABBREVIATIONS 
 
AUC Area Under the Curve 
CABG Coronary Artery Bypass Graft 
CCS Canadian Cardiovascular Society 
CS Case Series 
CHD Coronary Heart Disease 
ISTAHC International Society Technology Assessment in Health Care 
LVEF Left Ventricular Ejection Fraction 
MET Metabolic Equivalent Tests 
MM Medical Management 
MSAC Medicare Services Advisory Committee 
PMR Percutaneous Myocardial Revascularisation 
PTCA Percutaneous Transluminal Coronary Angioplasty 
QALM Quality Adjusted Month 
QALY Quality-adjusted Life Year 
RCT Randomised Controlled Trial 
SAQ Seattle Angina Questionnaire 
TMLR  Transmyocardial Laser Revascularisation 
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1. INTRODUCTORY REMARKS 
 
The basic mechanism of ischaemic cardiac pain (angina pectoris) is a mismatch between 
the demand for both coronary blood flow and oxygen delivery and the available supply.
1
 
Typically, it is a gripping or crushing central chest pain or discomfort that may be felt around 
the whole chest or deep within the chest.
2
 The pain may radiate into the neck or face and, 
rarely, into the teeth, back or abdomen. It is associated with heaviness, paraesthesia or pain 
in one (usually the left) or both arms. Typically, it is provoked by exercise and is promptly 
relieved by rest. 
 
Most patients with angina due to coronary artery disease respond adequately to treatment 
with anti-anginal medication, coronary angioplasty, with or without stenting, or coronary 
artery bypass surgery.
3
 Some patients, however, present with angina that is refractory to 
such treatments, generally because the coronary disease is diffuse and in the distant part of 
their coronary circulation, or because they are too unwell to undergo bypass surgery. 
Transmyocardial laser revascularisation (TMLR) is a new technique that uses laser ablation 
to create transmural channels in the ischaemic myocardium. Animal studies have shown 
improvements in mortality, decreases in infarct size, and preservation of contractile function. 
Early results of TMLR in human beings, sometimes used in combination with coronary artery 
bypass surgery, were encouraging. 
 
Early publications were largely favourable.
4-8
 However, these studies were all case series. In 
1999, there have been four randomised controlled studies published.
3,9-11
 The studies by 
Burkhoff, Allen and Frazier showed largely favourable results, in contrast to the study by 
Schofield, which concluded that the technique could not be recommended. Accompanying 
editorials in The Lancet
12
 and The New England Journal of Medicine
13
 have also 
recommended caution. 
 
The purpose of this Guidance Note is to review the evidence of effectiveness for the use of 
TMLR in patients with angina not controlled by medication or amenable to surgery. In 
addition, an economic analysis of this treatment is described. 
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2. DESCRIPTION OF UNDERLYING DISEASE 
 
2.1 CORONARY HEART DISEASE 
 
Coronary heart disease (CHD) is the most common cause of death in the UK with 110,000 
deaths in England in 1998. In nearly all cases, coronary artery disease is due to 
atherosclerotic changes;
1
 other causes include syphilis, various forms of arteritis, coronary 
embolism, and connective tissue disorders. 
 
There are numerous classifications of coronary heart disease by type. The following has 
been suggested:
1
 
 
- asymptomatic coronary heart disease, manifested by induced myocardial ischaemia; 
- sudden death; 
- stable angina pectoris; variant (Prinzmetal's) angina; coronary spasm; 'silent ischaemia'; 
- unstable angina pectoris; 
- acute myocardial infarction; 
- cardiac failure; 
- cardiac arrythmias or atrioventricular conduction defects. 
 
There are marked variations in mortality rates across the country:
14
 
 
- Geography. Mortality is higher in the north of England; 
- Social Class. There is a consistent trend in mortality rates. The lowest rates are in           
Social Class I and the highest in Social Class V; 
- Ethnicity. Mortality varies between ethnic groups.  Mortality from CHD is higher in people 
from the Indian subcontinent. 
 
The risk factors for CHD are well documented:
14
 
 
- Smoking - Estimated to account for up to 18% of CHD deaths. For those who smoke, 
stopping smoking is the single most effective means of reducing risk of CHD; 
- Hypertension; 
- Raised plasma cholesterol; 
- Inadequate physical activity; 
- Excessive alcohol consumption; 
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- Obesity;  
- Salt intake; 
- Diabetes. 
 
The Welsh Heart Survey and the British Regional Heart Study estimated that 25% of middle 
aged men showed some evidence of heart disease, amounting to 1.74 million people under 
the age of 65 in England and Wales.
15
 
 
Analysis of information derived from general practitioner medical records held on the 
General Practice Research Database allows an estimate of the prevalence of treated 
coronary heart disease per 1,000 patients.
16
 For males in 1996, the age standardised 
prevalence of treated coronary heart disease was 34.7 per 1,000 patients. For females in 
1996, the age standardised prevalence of treated coronary heart disease was 20.8 per 
1,000 patients. 
 
In the practices participating in the Trent Focus (a network of general practices willing to 
collaborate in research to facilitate high quality, co-ordinated primary health care-based 
research in Trent) the mean prevalence of ischaemic heart disease in practices with 
complete data was 3.84%.
17
 By comparison, for practices participating in the Collection of 
Health Data from General Practice project, the mean prevalence was 2.97%. 
 
Table 1 Estimates for Ischaemic Heart Disease for a 'Typical' Primary Care 
Group of 100,000 Population and a Health Authority of 500,000 
 
 PCG HA 
Ischaemic heart disease (Prevalence) 2,970
a
 - 3,840
b
 14,850
a
 - 19,200
b
 
   
Angina (Incidence) 83
c
 415
c
 
 
a Mean prevalence of 2.97%.  
b Mean prevalence of 3.84%.  
c Crude incidence of 8.3 per 10,000 per annum (see text above for references). 
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2.2 ANGINA 
 
The primary cause of angina is insufficient supply of oxygen to the myocardium. This is 
usually provoked by exertion but can occur at rest; severity and prognosis are variable. 
Several studies have attempted to estimate the incidence and prevalence of angina. These 
studies are quite variable in their estimates, reflecting their different study populations. The 
annual consultation rate within general practice is around 70 per 10,000 patients
18
 with a 
male to female ratio of 4 to 3. The same authors estimate the five-year prognosis as follows: 
 
 -  death      20% 
 -  no symptoms or controlled without medication 15% 
 -  symptoms well controlled with medication  35% 
 -  moderate control with medication   20% 
 -  severe symptoms     10% 
 
The Fourth National General Practice Morbidity Study
19
 found that the number of patients 
who consulted their GP at least once during the year for angina was 130 and 98 per 10,000 
person years at risk for men and women respectively. This represents a 60-69% increase 
since the previous GP Morbidity Survey carried out in 1981. The survey estimated that the 
incidence of new and first-time episodes of angina was 55 and 49 per 10,000 person years 
at risk in men and women respectively. Gandhi et al.
20
 found an overall crude incidence of 
8.3 per 10,000 per annum in patients aged 31-70 years of age. 
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3.  CURRENT SERVICE PROVISION 
 
3.1 MEDICAL TREATMENT 
 
The investigations and treatments that people with stable angina should usually be offered 
unless contraindicated are:
21
 
 
Aetiological investigations: 
- Haemoglobin, 12 lead resting ECG. 
 
Estimation of risk: 
- Plasma glucose, serum cholesterol; 
- Assessment of severity of myocardial ischaemia (e.g. Exercise ECG, thallium scan). 
 
Treatment to relieve symptoms: 
- Sub-lingual nitrates for immediate symptom control; 
- Background beta blockers and/or nitrates and/or calcium antagonists. 
 
Treatment to reduce cardiovascular risk: 
- Advice about how to stop smoking including advice about the use of nicotine 
replacement therapy; 
- Information about other modifiable risk factors and personalised advice about how they 
can be reduced (this includes advice about physical activity, diet, alcohol consumption, 
weight and diabetes); 
- Advice and treatment to maintain blood pressure below 140/85 mmHg; 
- Low dose aspirin (75mg daily); 
- Statins and dietry advice to lower serum cholesterol concentrations either to less than 
5mmol/l (LDL-C to below 3mmol) or by 30% (whichever is greater); 
- Education about symptoms of heart attack and, should they develop, instruction to seek 
help rapidly by calling '999'. 
 
When angina occurs frequently or with only modest exertion, regular prophylactic therapy 
should be advised. This consists of nitrates, beta adrenergic blocking drugs or calcium 
antagonists.
2
 Aspirin, and, where appropriate, statin therapy to lower cholesterol should be 
given. 
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Information is available on the number of prescriptions for each type of medication. 
However, it is not possible to identify from this information the indication for the prescription. 
In 1996, an age standardised rate of 36.2 per 1,000 male patients, and 43.5 per 1,000 
female patients were prescribed beta adrenoceptor blocking drugs. The comparable rate for 
nitrates and calcium channel blocking drugs in 1996 was 43.7 per 1,000 male patients, and 
35.8 per 1,000 female patients. 
 
A recent review of treatments for chronic stable angina
22
 found that:  
 
- few studies exist of the long-term effectiveness of medical treatment with little evidence 
of large differences between different classes of drug; 
- there is little evidence on patients’ quality of life; 
- no UK cost or cost-effectiveness studies were identified. 
 
3.2 CORONARY ANGIOPLASTY 
 
This is a technique of dilating coronary atheromatous obstructions by inflating a balloon 
against the obstruction.
2
 The balloon, which is mounted on the tip of a very thin catheter, is 
inserted through the obstruction using X-ray fluoroscopy, and it is then inflated with dilute 
contrast material. Multiple inflations of the balloon using a pressure of several atmospheres 
will squash and crush the atheroma and relieve the obstruction. This technique is widely 
applied for the treatment of angina due to isolated, proximal, non-calcified, atheromatous 
plaques, usually in patients with a relatively short history of coronary ischaemia. Multiple 
lesions may be treated and repeat procedures can be undertaken. 
 
Evidence supports percutaneous transluminal coronary angioplasty (PTCA) in terms of relief 
of angina, but evidence on myocardial infarction rates is conflicting.
22
 Clinical benefit is 
apparently reflected in improved health-related quality of life, although information on long-
term effects of revascularisation is lacking. 
 
3.3 CORONARY ARTERY BYPASS GRAFT 
 
Surgical treatment of angina is considered when medical management is no longer 
sufficient, and for severe disease. A vein (usually saphenous) or internal mammary artery is 
used to bypass the areas of occlusion. Coronary artery bypass grafts (CABG)s have 
mortality benefits for up to five years, and possibly longer, compared with medical therapy, 
 9 
 
particularly in patients with a greater extent of disease.
22
 CABGs are most cost-effective in 
patients with severe angina, left main vessel disease and multi-vessel disease. 
 
By international standards, the UK has high rates of CHD, but low rates of coronary artery 
revascularisation.
23,24
 There are marked geographical, gender and racial variations in 
revascularisation rates which are not closely correlated with measures of the level of heart 
disease in the community.25-27 The National Service Framework for Coronary Heart Disease 
recommends a substantial increase in revascularisation rates and a renewed effort to 
reduce inequities in treatment rates.
21
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4. DESCRIPTION OF NEW INTERVENTION 
 
In the reptilian heart, the myocardium has a sinusoidal structure and the myocardium is 
perfused by passive diffusion of oxygenated blood. This concept stimulated interest in a 
technique that potentially allowed oxygenation of human myocardium by the same means. 
In TMLR the heart is exposed through a left anterolateral thoracotomy. A laser (carbon 
dioxide or Holmium) is then applied to the epicardial surface of the left ventricle, and 
sufficient energy applied to create small channels, from the epicardial to endocardial 
surface, in areas of myocardium previously identified as ischaemic.
13
 The laser is 
synchronised with the heartbeat and automatically fires when the ventricle is filled with 
blood.
28
 Remaining laser energy is absorbed by the blood, preventing damage to other heart 
tissue. Typically, 10 to 50 channels are created. 
 
Three possible mechanisms have been suggested, but the actual mode of action is unclear: 
 Direct revascularisation i.e. the laser created channels remain patent and oxygen 
diffuses directly to the myocardium; 
 Stimulation of angiogenesis i.e. new vessel formation; 
 Myocardial denervation. 
 
Transmyocardial laser revascularisation is suggested for the treatment of patients with Class 
III or Class IV stable angina not amenable to medical treatment and conventional coronary 
revascularisation, according to the Canadian Cardiovascular Society (CCS) classification 
system for angina.
28
  
 
Table 2 The Canadian Cardiovascular Society Grading of Angina. 
 
Class I Ordinary physical activity does not cause angina. (Strenuous 
physical activity provokes angina). 
Class II Slight limitations of ordinary physical activity. (Climbing more 
than one flight of stairs or walking uphill provokes angina). 
Class III Marked limitation of ordinary physical activity. (Walking on the 
level or climbing one flight of stairs provokes angina). 
Class IV Inability to carry on any physical activity. (Angina may be 
present at rest). 
Note: Limitations to normal activity are: class I - none; class II - slight; class III - marked; class IV - severe. 
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Most patients treated in clinical trials have already received at least one bypass graft and 
are at high risk of re-operation. For medical reasons, these patients are not expected to 
benefit from angioplasty. It has been estimated that 80,000 Americans qualify for TMLR 
annually.
28
 
 
4.1 POTENTIAL COST (CANADIAN CO-ORDINATING OFFICE FOR HEALTH 
TECHNOLOGY ASSESSMENT, 1998) 
 
The Heart Laser
TM
 (PLC Medical Systems, Inc.) sells for US $400,000; the disposables for 
each procedure sell for US $1,500. The operation takes approximately two hours to 
complete and does not require a heart-lung machine. The average hospital stay following 
TMLR ranges from five to seven days and is generally less than the recovery time following 
CABG. 
 
4.2 PERCUTANEOUS MYOCARDIAL REVASCULARISATION  
 
Percutaneous myocardial revascularisation (PMR) is also a method of treatment for patients 
with refractory angina. In comparison with TMLR, it is a less invasive procedure. In the UK a 
trial is currently being undertaken at Papworth Hospital where patients are being 
randomised to either PMR or medical therapy. Initial findings at 12 months indicate that for 
PMR patients mean exercise time on the treadmill increased by 79 seconds, compared to an 
increase of 35 seconds for the medical therapy group (p=0.028). In comparison with TMLR, 
there is evidence to suggest that there are fewer post-operative complications, and that the 
mortality rate is lower, for patients receiving PMR (Tait - Personal Communication 2000). 
 
 12 
 
5. METHODS 
 
The medical literature was searched in order to identify relevant studies for inclusion in this 
paper. Searches on EmBASE, MEDLINE, and Cochrane Library were undertaken using the 
following search strategy. 
 
 #1 transmyocardial laser revascularisation; 
 #2 laser* and revasculari* and angina*; 
 #3 #1 or #2 (169 records); 
 #4 #1 or #2 (86 records). 
 
All databases were searched from 1990 onwards. Papers identified in this search were 
supplemented with recently published literature from known journals. Papers retained for 
inclusion in this study were required to be papers reporting the results of randomised 
controlled trials (RCT)s or case series studies. If papers reporting findings produced results 
in an interim paper, this was discarded in situations where a paper reporting the final 
findings of the study was available. 
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6. RESULTS 
 
6.1 QUANTITY AND QUALITY OF RESEARCH AVAILABLE 
 
6.1.1. Quantity and Type of Evidence Available 
 
A total of ten studies were identified, two of which were rejected because they had 
preliminary results of patients who were included in later studies,
6,29
 leaving eight studies for 
the review (see Table 3). In 1999 four RCTs comparing this procedure to the medical 
treatment of angina, were published, and a further four case series have described the 
results of the procedure. 
 
Table 3 Summary of Studies Included in the Review 
 
Authors Setting Study Patient Groups 
Allen et al. (1999)
10
 USA RCT Transmyocardial revascularisation 
followed by continued medical 
therapy (n=132) vs medical therapy 
alone (n=143).  
Burkhoff et al. (1999)
9
 USA RCT Transmyocardial revascularisation 
and continued medication (n=92) vs 
medical therapy alone (n=90). 
Frazier et al. (1999)
11
 USA RCT Transmyocardial revascularisation 
(n=91) vs continued medical 
treatment (n=101). 
Schofield et al. (1999)
3
 UK RCT Transmyocardial revascularisation 
plus normal medication (n=94) vs 
continued medication alone (n=94). 
Cooley et al. (1996)
8
 USA CS Transmyocardial revascularisation 
(n=21). 
Horvath et al. (1997)
5
 USA CS Transmyocardial revascularisation 
(n=200). 
Vincent et al. (1997)
7
 Switzerland CS Transmyocardial revascularisation 
(n=268). 
Nagele et al. (1998)
4
 Germany CS Transmyocardial revascularisation 
(n=60). 
Note: CS = Case series 
 14 
 
Some papers include patients who have received TMLR in addition to CABG or PTCA. Due 
to the small numbers of such patients that have been reported, the results from this sub-
group of patients are not described further in this analysis. 
 
The quality of the published studies is variable with several problems when attempting to 
compare studies: 
 
 Inclusion criteria vary between studies. In particular, the degree of severity of angina - in 
most studies patients were predominantly Class IV on the CCS classification of angina, 
but some studies included patients with Class III. No study reported results separately by 
level of severity at baseline. 
 
 Some studies accepted patients with a left ventricular ejection fraction (LVEF) as low as 
20% whereas other studies had a higher threshold. This difference is particularly 
significant when comparing mortality rates as there is a clear correlation between very 
low LVEF and death. 
 
 Some studies did not state the number of patients who had been excluded from further 
treatment having been referred for inclusion. Those studies that did report the number of 
exclusions typically excluded half the patients referred to them. 
 
 Follow-up was brief. Only one study reported results at three years whilst the other 
studies typically reported at 12 months follow-up. 
 
 Reporting of methods was variable. For example, two of the RCTs did not report if 
statistical power had been estimated.
10,11
 
 
 The numbers of patients were small in most studies. This was aggravated by the fact 
that two of the RCTs permitted patients originally assigned to receive medical treatment 
to then have TMLR if their angina remained severe.
10,11
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6.1.2 Outcome Measures 
 
All studies used the CCS grading of angina (see Table 2). Relief of angina is typically 
defined as an improvement of at least two classes on this scale from baseline. 
 
6.2 EVIDENCE OF EFFECTIVENESS 
 
Despite the fact that there have only been 10 published studies, a large number of different 
outcome measures have been used: These are tabulated in Table 4, where a ‘v’ denotes 
that the outcome was used in the study. 
 
Table 4 Outcome Measures Used in the Studies 
 
 Study Number (see footnote) 
Outcome Measure 1 2 3 4 5 6 7 8 
Survival v v v v v v v v 
Mortality v v v v v v v v 
Angina relief v v v v v v v  
Hospital admissions v v v v  v   
Use of cardiac medications v v v v  v  v 
Myocardial perfusion v v v v v v v v 
LVEF  v  v v  v  
Exercise capacity v v  v v  v  
Echocardiography  v   v  v  
Stress test  v     v  
Chest pain    v     
Positron tomography      v   
SF-36   v v*     
Euroqol    v*     
Seattle Angina Questionnaire  v v      
Duke Activity Status Index v        
Unspecified quality of life       v  
Study: 1 - Allen et al.; 2 - Burkhoff et al.; 3 - Frazier et al.; 4 - Schofield et al.; 5 - Cooley et al.; 6 - Horvath et al.;  
7 - Vincent et al.; 8 - Nagele et al. 
Note. * Used, but not reported in this paper for the study. 
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6.2.1 Outcomes Related to Mortality 
 
By definition, patients receiving this treatment are very sick and, thus, are expected to have 
a limited life expectancy. This emphasises the need to have a good control group in any 
study. Some studies included sicker patients than others (i.e. more severe disease) and, 
thus, it is difficult to compare mortality rates across different studies. No studies 
demonstrated improvements in survival 12 months after TMLR. 
 
Peri-operative mortality rates (defined as deaths within 30 days of procedure) varied 
markedly across studies: this may reflect different inclusion criteria or could be due to better 
operative and anaesthetic techniques, perhaps related to greater experience with the 
procedure. 
 
The results presented in Table 5 indicate that there is no statistical difference in mortality 
between the two treatment methods, with no significance indicated in the four RCTs. The 
level of significance is so low that combining the studies into a meta analysis would be 
unlikely to produce a significant result. 
 
6.2.2 Outcomes Related to Relief of Angina 
 
If relief of angina is defined as a reduction of at least two classes in the CCS score, then 
there is good evidence to suggest that TMLR is effective at relieving the pain of angina. All 
four RCTs showed a significant advantage comparing TMLR to medical treatment. 
 
The rate of hospital admissions for angina is also reduced by TMLR. However, only one 
study
3
 reports the total number of hospital admissions, including those due to complications 
from the procedure: they found no difference between the two groups in the total number of 
hospital admissions. 
 
Use of cardioactive medications is also reduced by TMLR.  
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Table 5 12 Month Survival Following TMLR or Medical Treatment & Number and 
Proportion of Deaths from TMLR within 30 days of Procedure 
 
 12 Month Survival Proportion of Deaths in 30 Days 
Study Proportion Alive at  
12 Months 
Sig Number of Deaths % 
Frazier et al.
11
 TMLR - 85% (of 91 
patients) 
Medical - 79% (of 41 
patients) 
 
NS 
(p=0.5) 
3 (of 91 patients) 
 
2 (of 41 patients) 
3.3% 
 
4.9% 
Burkhoff et al.
9
 TMLR - 95% (of 92 
patients) 
Medical - 90% (of 90 
patients) 
 
 
NS 
1 (of 92 patients) 
 
0 (of 90 patients) 
1.1% 
 
0% 
Allen et al.
10
 TMLR - 84% (of 132 
patients) 
Medical - 89% (of 143 
patients) 
 
 
NS 
(p=0.2) 
7 (of 132 patients) 
 
2 (of 97 Patients) 
0.8% 
 
2.1% 
Schofield et al.
3
 TMLR - 89% (of 94 
patients) 
Medical - 96% (of 94 
patients) 
 
 
NS 
(p=0.1) 
5 (of 94 patients) 
 
Not Stated 
 
5.3% 
 
- 
Vincent et al.
7
 TMLR – 90.5% (of 124 
patients) 
N/A 1 (of 124 patients) 0.8% 
Cooley et al.
8
 TMLR – 76.2% (of 21 
patients) 
N/A 4 (of 21 patients) 19.0% 
Nagele et al.
4
 TMLR – 76.7% (of 60 
patients) 
N/A 7 (of 60 patients) 11.7% 
Horvath et al.
5
 TMLR – 82.5% (of 200 
patients (at 10 months) 
N/A 18 (of 200 patients) 9.0% 
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Table 6 Relief of Angina at 12 Months (Defined as Reduction in CCS Score of at Least 2 Classes), Rate of Hospital Admission 
for Angina within 12 Months and Use of Medications 
 
Study Proportion with Relief of Angina 
 
Hospital Admissions Use of Medications 
Frazier et 
al.
11
 
- TMLR 
- Medical including 
crossover* 
- Medical without 
crossover* 
 
- 72% (of 61 patients) 
- 43% (of 54 patients) 
 
- 13% (of 20 patients) 
 
p<0.001 
2% of TMLR patients admitted with unstable 
angina. 
69% of medical patients admitted with 
unstable angina. 
 
p<0.001 
Use of cardioactive medications decreased or 
remained unchanged in 83% of the patients in whom 
TMLR was successful. Use of medications increased 
or remained unchanged in 86% of the patients 
assigned to medical treatment. 
 
Burkhoff et 
al.
9
 
- TMLR 
- Medical 
 
- 61% (of 77 patients) 
- 11% (of 73 patients) 
 
Significance level not 
stated 
37 admissions due to unstable angina in TMR 
group (92 patients). 
69 admissions due to unstable angina in 
medical group. 
 
States 'little change in the overall pattern of 
medications during the study' (no further details given). 
 
Allen et al.
10
 - TMLR 
- Medical including 
crossover* 
- Medical without 
crossover* 
 
- 76% (of 76 patients) 
- 78% (of 37 patients) 
 
- 32% (of 50 patients) 
 
p<0.001 
39% of TMLR patients had cardiac related 
hospitalisations. 
67% of medical patients had cardiac related 
hospitalisations. 
 
p<0.001 
Calcium channel blockers reduced in the TMLR group 
(p=0.002). 
Beta blockers reduced or discontinued in the TMLR 
group (p=0.02). 
Nitrates reduced in the TMLR group (p=0.12). 
Schofield et 
al.
3
 
- TMLR 
- Medical 
-  25% (of 74 patients) 
- 4% (of 78 patients) 
 
 
p<0.001 
TMLR patients had average 0.5 admissions 
with angina. 
Medical patients had average 0.8 admissions 
with angina. 
p=0.015 
Reduced use of calcium antagnosists in the TMLR 
group (p<0.001). Reduced use of nitrates in the TMLR 
group (p=0.025). 
 
Vincent et al.
7
 Not possible to calculate from data in paper 
 
Not stated. N/A 
Cooley et al.
8
 - TMLR - 85% (of 13 patients) Not stated. N/A 
Nagele et al.
4
 Not possible to calculate from data in paper 
 
7% admitted with unstable angina. N/A 
Horvath et 
al.
5
 
- TMLR -  74% (of 95 patients) In the year prior to TMLR, patients averaged 
2.5 admissions for angina.  In the year 
following TMLR there was an average of 0.4 
admissions. 
P<0.001 
12 months after TMLR, 56% had reduced their 
cardioactive medications whilst 19% had increased 
use. 
 
*These studies allowed patients who had been assigned to medical treatment to receive TMLR if severe angina persisted. The results of these studies are presented separately for those 
who received TMLR (crossover) and those who did not.  
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6.2.3 Outcomes Related to Functional Capacity of the Heart 
 
One RCT,
11
 and one other study
5
 demonstrated objective improvements in myocardial 
perfusion; the three other RCTs showed no improvement. The significance of this is that the 
most favoured mechanism of action for TMLR is that it stimulates new vessel formation; if 
this is the mechanism of action then one would expect an improvement in myocardial 
perfusion. 
 
LVEF was not measured in two of the RCTs and two of the case series. Only one study
7
 
showed an improvement. 
 
Most studies show an increase in exercise capacity although one of the RCTs
3
 did not. 
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Table 7 Myocardial Perfusion, Left Ventricular Ejection Fraction and Exercise Capacity 
 
Study Myocardial Perfusion Results LVEF Exercise Capacity 
Frazier et al.
11
 Myocardial perfusion (calculated as the number of 
defects at baseline minus the number of defects at 
follow-up, divided by the number of defects at baseline) 
improved by 20% in the TMLR group and worsened by 
27% in the medical treatment group (p=0.002). 
Not measured at follow-up. N/A 
Burkhoff et al.
9
 At 12 months the median proportion of the myocardium 
affected by ischaemia was 11.5% in the TMLR group 
and 12% in the medication only group (not statistically 
significant). 
 
LVEF did not change 
significantly in the medication 
only group from baseline to 3 
months (median change 0%). In 
the TMLR group, the median 
change from baseline to 3 
months was a decrease of 3%. 
 
Exercise tolerance test. 
TMLR - median time (baseline) - 364 sec (range 
105 - 981) 
 - median time (12 months) - 429 sec 
medical management (MM) - median time 
(baseline) - 381 sec (range 89 - 747) 
 - median time (12 months) - 335 sec 
Median difference 111 sec, p<0.0001 between 
groups. 
Allen et al.
10
 No significant differences with respect to changes in 
ischaemia, defects in perfusion at rest or delayed 
effects. 
No correlation between improvement in angina and the 
results of thallium scanning. 
 
Not measured at follow-up. 
 
Treadmill test (results expressed as metabolic 
equivalents (MET)). 
TMLR - MET of 5.0, MM - MET of 3.9 (p=0.05). 
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Schofield et al.
3
 In both TMLR and medical groups the number of sites 
with reversible ischaemia decreased and the number 
with irreversible ischaemia increased. The overall 
number of sites with reversible ischaemia did not differ 
significantly between groups, but there is a small 
excess of sites with irreversible ischaemia among 
TMLR patients. 
 
Mean LVEF was 49% at 
baseline in the medical group 
and 48% in the TMLR group. At 
12 months, the mean LVEF was 
48% in the medical group and 
46% in the TMLR group. 
Treadmill exercise time. 
At 12 months the mean improvement in exercise 
time in the TMLR group was 40 seconds longer 
than in the medical group (NB: no baseline 
values stated). 
Vincent et al.
7
 At 12 months, 27% had better perfusion, 45% had 
identical, and 18% worse. 
 
Compared to baseline, LVEF 
was better or identical in 78% of 
patients at 12 months. 
Ergometry stress test. 
At 12 months, 64% of TMLR patients had a better 
result, 14% identical, 21% worse. 
Cooley et al.
8
 Average perfusion of the laser treated regions 
increased from 45% of normal at baseline to 51% of 
normal at 12 months; the perfusion of the non-lasered 
segments decreased from 73% of normal at baseline 
to 70% of normal at 12 months (differences not 
statistically significant). 
 
Mean LVEF was 48% at 
baseline and 50% at 12 months. 
Treadmill test. 
Mean time at baseline 4.3 mins; at 12 months 
mean time had increased to 10.0 mins. 
Nagele et al.
4
 Increase in moribund and decrease in normal cardiac 
segments at 12 months (p<0.05) i.e. worsening of 
perfusion. 
 
 
 
 
Not measured at follow-up. N/A 
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Horvath et al.
5
 Treated area showed a statistically significant 
decrease in the number of segments with reversible 
perfusion defects, and no change in the number with 
fixed defects, at 12 months. Untreated area showed no 
significant change in either fixed or reversible defects. 
 
Not measured at follow-up. N/A 
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6.2.4 Outcomes Related to Quality of life 
 
This is difficult to assess as only four studies included an assessment of quality of life; three 
different assessment tools were used and one study did not state which tool was used. 
However, all four studies showed an improvement in the quality of life of patients following 
TMLR. 
 
Table 8 Quality of Life 
 
Study Quality of Life Data 
Frazier et al.
11
 Used SF36 and Seattle Angina Questionnaire (SAQ). 
Using the SF36, the TMLR group improved significantly more (38% 
improvement) than the medical group (6% improvement) at 3 months, 
and this difference was also significant at 6 and 12 months (p<0.001 
at 3 month, p=0.01 at 6 month and p<0.001 at 12 month). 
For each of the 15 components of the SAQ the TMLR group scored 
significantly better (no details given). 
 
Burkhoff et al.
9
 Used SAQ 
At 3, 6 and 12 months, scores of each quality of life index in the SAQ 
were significantly better in the TMLR group than in the medication 
only group (no details given in the text). 
 
Allen et al.
10
 Used Duke Activity Status Index (a scale of 0 to 58, higher scores are 
better). 
At 12 months, the TMLR group had a mean score of 21 compared to 
12 for the medical group (p=0.003). 
 
Schofield et al.
3
 Collected quality of life data, but not reported in this paper. 
 
Vincent et al.
7
 67% reported an improvement, and 21% steady state, in their well- 
being. No details given of assessment tool used. 
 
Cooley et al.
8
 N/A 
Nagele et al.
4
 N/A 
Horvath et al.
5
 N/A 
 
 24 
 
6.3 ECONOMIC ANALYSIS 
 
There are no known published papers which report the costs or cost-effectiveness of the 
TMLR treatment, though a recent report by the Medicare Services Advisory Committee 
(MSAC)
30
 contains cost information and a cost-effectiveness analysis. None of the studies 
assessed or reported within this Guidance Note reports the costs of the intervention, and 
only a small number of the papers make any reference to the quality of life benefits resulting 
from the intervention.  
 
Papers on the costs and health-related quality of life information from the Schofield et al.
3
 
trial are forthcoming, but are not yet available to use in the analysis presented here. 
However, it is possible to use utility results from this study which were presented as part of a 
recent conference abstract. 
 
In view of the lack of published research evidence on the cost-effectiveness of TMLR, this 
paper attempts to estimate the costs and benefits of TMLR using a spreadsheet modelling 
approach. The modelling assumptions are made using evidence of benefits from the 
Schofield et al.
3
 study and costing information presented in the MSAC report.
30
  
 
It is likely that further information on both the benefits and costs will become available in due 
course, but it was not available in time for this document. 
 
6.3.1 Estimation of Net Benefits 
 
Health related quality of life for TMLR vs medical management (MM) was considered in the 
Schofield et al.
3
 study, but was not reported in their paper. Additional information reporting 
this analysis in terms of EuroQol utility scores was presented in abstracts submitted to the 
International Society Technology Assessment in Health Care (ISTAHC) conference held in 
Rotterdam in 1999. Further papers reporting this analysis are in preparation, but are not yet 
available for consideration here. 
 
The ISTAHC abstract EuroQol utility scores have been used to estimate Quality-Adjusted 
Months (QALM)s and hence Quality-Adjusted Life Years (QALY)s for each of the treatment 
options. The area under the curve (AUC) was modelled using a simple spreadsheet 
approach in order to estimate QALMs (see Table 9). 
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The total number of QALMs, and hence QALYs, for all the individuals in each of the 
treatment arms in the Schofield et al.
3
 trial was estimated. This allows a calculation of the 
average values across individuals and, thus, the total QALMs attributed to the numbers of 
patients remaining in the study at differing time points as referenced by the survival analysis 
reported by Schofield et al.
3
 It should be stressed that uncertainty exists in interpreting these 
utility values and also the numbers of survivors in the trial as the actual number of survivors 
is unknown. 
 
Table 9 EuroQol Utility Scores 
 
 EuroQol utility value 
 Base 3 months 1 year* 2 year* 3 year 
TMLR 0.44 0.54 0.52 0.50 0.48 
MM 0.43 0.44 0.46 0.50 0.53 
Data contained in an abstract submitted to the ISTAHC conference. 
* Extrapolated values (linear). 
 
6.3.2 Estimation of Net Costs 
 
The MSAC report disaggregated costs during the first year; these gave the procedure costs 
for TMLR as Aus $10,748 (£4,299 assuming £1 = Aus $2.50), costs for TMLR equipment as 
Aus $5,800 (£2,320), costs or hospitalisations for unstable angina as Aus $60 (£24), with 
the cost for complications as Aus $930 (£372). Comparable costs for medical management 
were Aus $4,102 (£1,641) for hospitalisations for unstable angina, and Aus $907 (£363) for 
complications. Thus, year 1 total costs are estimated at Aus $17,539 (£7,016) for TMLR and 
Aus $5,009 (£2,004) for medical management. Costs for subsequent years were given as 
Aus $712 (£285) for TMLR and Aus $5,009 (£2,004) for medical management. A significant 
difference between these two costs is the cost of hospitalisations for unstable angina. These 
hospitalisation costs were derived by applying a cost per episode of Aus $2,994 to assumed 
treatment rates of 0.02 episodes per patient per annum for TMLR and 1.37 episodes per 
patient per annum for medical management. These assumed unstable angina health 
benefits of TMLR have been heavily criticised by MSAC and are said to be biased in favour 
of TMLR. Bearing this in mind, the costs for subsequent years are then given as Aus $712 
(£285) for TMLR and Aus $5,009 (£2,004) for medical management. The implication of 
these costing assumptions is that during year 4, the total cost of TMLR will be overtaken by 
that for medical management. This outcome is heavily dependent on the validity of the 
hospitalisation assumptions used.  
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Due to differences in treatment patterns, for example, costs in Australia are unlikely to be 
the same as in the UK. For the purposes of the modelling reported in the following section 
these, however, are the assumptions that have been used. 
 
6.3.3 Estimation of Cost-effectiveness and/or Cost-utility 
 
The MSAC report undertook a cost-effectiveness analysis to a three year duration. The 
report found that the incremental cost of TMLR to MM was Aus $12,530 (£5,012) in the first 
year with savings occurring in the second and third years if the response to TMLR is 
sustained through symptom relief. Additional incremental cost-effectiveness ratios were 
calculated within the report. The ratio for the first year after TMLR per extra patient free of 
unstable angina was Aus $18,159 (£7,264) and per extra patient free of disabling angina 
was Aus $21,237 (£8,495).  
 
The MSAC report highlights the fact that the projected savings for both the second and third 
years, post TMLR, are based upon the assumption that the treatment effect is sustained and 
that the chance of having disabling angina remains unchanged in both the TMLR and MM 
groups. This assumption remains central to the claimed cost savings of TMLR, but it also 
lacks substantiated evidence. The report concludes that further evidence on the long-term 
effectiveness and cost-effectiveness of TMLR would be required in order to support these 
claims further.
30
 
 
In order to model the cost-effectiveness of TMLR, in this paper the utility values from the UK 
study have been combined with the costs detailed within the MSAC report. Once again, it 
should be reiterated that these figures are subject to considerable uncertainty and should be 
up-dated by further findings from the UK trial as soon as they become available. 
 
However, bearing the above assumptions in mind, the incremental costs per QALY for the 
first three years are reported in Table 10. 
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Table 10 Incremental Costs per QALY (costs and benefits discounted at 6%) 
 
 Incremental Cost per QALY  
(based over three different time periods) 
 Year 1 Year 2 Year 3 
TMLR vs MM £89,092 £61,497 £45,815 
 
Clearly, these figures suggest that the costs of TMLR are expensive relative to the reported 
QALY gain. Extrapolation further into the future suggests that these ratios will decrease 
moderately, but this assumes that the years following laser treatment require only minimal 
costs and no additional laser treatment and that the health benefits remain. 
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7. EQUITY ISSUES 
 
It is widely acknowledged that there are distinct national and local variations in the rates of 
treatment for angina. Utilisation will be influenced by a variety of factors. Firstly, there is a 
requirement to consider need. The epidemiology of the disease dictates that this will vary 
from location to location, even when differences in age and population structure are 
adjusted for. Secondly, demand will vary and will be dependent upon factors such as patient 
consultation thresholds, GP referral thresholds and clinician referral and intervention 
thresholds. Finally, supply may be important within the context of this procedure, because 
the location of the equipment to undertake the procedure will be restricted to specialist 
centres. 
 
Given that there is good evidence that the inverse care law applies in relation to the 
provision of interventional cardiology,
26
 it is essential that any additional investment in 
revascularisation treatments is targeted towards those in greatest need. 
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8. OPTIONS FOR PURCHASERS/COMMISSIONERS 
 
Given that the published evidence for the effectiveness of this procedure is limited, it is not 
possible to make a definitive statement about the best option for commissioners. It is 
probable that the procedure will be of benefit to certain carefully defined sub-groups of 
patients. 
 
Option 1 Await Further Evidence 
 
Do not commission this procedure until further randomised controlled studies, preferably 
with economic analysis, and with longer periods of follow-up, have demonstrated that the 
procedure is effective, and there is clear evidence as to which sub-groups of patients are 
suitable. 
 
Option 2 Commission the Procedure for Selected Sub-groups of Patients 
 
Based on current evidence, this procedure would be commissioned for those sub-groups of 
patients for whom it appears to be of benefit. 
 
Option 3 Commission the Procedure as Part of Tertiary Cardiology Services 
 
Allow clinicians to use this procedure at their discretion, as one treatment modality within an 
overall package of tertiary cardiology services. 
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9. CONCLUSIONS 
 
Across all RCTs there were no significant differences demonstrated in 12 month survival 
rates. Similarly, peri-operative mortality rates (defined as death within 30 days of the 
procedure) were generally low, but varied across different studies. Greater rates were 
generally observed in the case series studies where sample sizes were small. The variation 
in rates might well reflect differing inclusion criteria or study samples and eliciting an 
interpretation is not obvious. 
 
If angina relief is defined as a reduction of at least two classes in the CCS score, then the 
results of all four RCTs imply that there is evidence to suggest that TMLR is effective at 
relieving the pain of angina. Rates of hospital admissions for angina also suggest that TMLR 
is effective, but only one study reports the total number of hospital admissions making the 
clarification of inferences difficult. The use of cardiac medications was also found to be 
reduced in those patients receiving TMLR. 
 
Two studies (one RCT) demonstrate improvements in myocardial perfusion, but the three 
remaining RCTs illustrated no improvement. Similarly, LVEF was improved in one of the 
case series studies, but was not shown to have improved in the two RCTs where it was 
measured. Exercise capacity was demonstrated to have increased in most studies, though 
one RCT did not illustrate an increase. 
 
Quality of life was assessed in just four of the studies, using differing instruments, thus 
making conclusions inconclusive. However, despite such diversity, all four studies reported 
that improvements in quality of life had been observed in patients who had undergone 
TMLR. 
 
Based upon these findings, it is unclear whether the benefits of TMLR are clearly proven in 
these studies. The findings in the four RCTs appear to be contradictory. In addition, it is 
unclear what the benefits are beyond a 12 month duration following the intervention - the 
length of follow-up in most of the studies. It is suggested that the clinical evidence does not 
present conclusive evidence for the superiority of the TMLR procedure and more research is 
required before unambiguous empirical support can be embraced. 
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There is insufficient economic analysis at present to reach a firm conclusion about 
the cost-effectiveness of TMLR. Using available data to model this, however, 
suggests that the cost per QALY is at least £45,000 and may be considerably more. 
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 Nick Payne  
  
97/02 Working Group on Acute Purchasing: Prostacyclin in the Treatment of   £10.00 
 Primary Pulmonary Hypertension (1997) by TW Higenbottam, SE Ward,   
 A Brennan, CJ McCabe, RG Richards and MD Stevenson. Series Editor:   
 Nick Payne.  
  
97/03 Working Group on Acute Purchasing: The Use of Riluzole in the Treatment £10.00 
 of Amyotrophic Lateral Sclerosis (Motor Neurone Disease) (1997) by J   
 Chilcott, P Golightly, D Jefferson, CJ McCabe and S Walters. Series 
Editor:  
 
 Nick Payne.  
  
97/04 Working Group on Acute Purchasing: Recombinant Factor VIII Versus   £10.00 
 Plasma Derived Factor VIII in the Management of Haemophilia A: An   
 Examination of the Costs and Consequences (1997) by C Green and   
 RL Akehurst. Series Editor: Nick Payne.  
  
97/05 Working Group on Acute Purchasing: The Use of Cisplatin and Paclitaxel £10.00 
 as a First Line Treatment in Ovarian Cancer (1997) by SM Beard, R   
 Coleman, J Radford and J Tidy. Series Editor: Nick Payne.  
  
97/06 Working Group on Acute Purchasing: The Use of Alpha Interferon in the  
 Management of Chronic Myeloid Leukaemia (1997) by RG Richards  
£10.00 
 and CJ McCabe. Series Editor: Nick Payne.  
  
97/07 Working Group on Acute Purchasing: Spinal Cord Stimulation in the   £10.00 
 Management of Chronic Pain (1997) by J Tomlinson, CJ McCabe and B 
Collett. Series Editor: Nick Payne. 
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97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in  £5.00 
 Adults (1997) by JN Payne and RG Richards. Series Editor: Nick Payne.  
 38 
 
97/09 Working Group on Acute Purchasing: A Review of the Use of Donepezil in  £10.00 
 the Treatment of Alzheimer’s Disease (1997) by FA Pitt, J Chilcott, P   
 Golightly, J Sykes and M Whittingham. Series Editor: Nick Payne.  
  
97/10 Working Group on Acute Purchasing: The Use of Bone Anchored Hearing  £10.00 
 Aids (1997) by NJ Cooper, J Tomlinson and J Sutton. Series Editor: Nick   
 Payne.  
  
98/01 Working Group on Acute Purchasing: A Review of the Use of Current 
 Atypical Antipsychotics in the Treatment of Schizophrenia (1998) by S 
 Beard, J Brewin, C Packham, P Rowlands and P Golightly. Series Editor: 
 Nick Payne. 
£10.00 
  
98/02 Working Group on Acute Purchasing: Internal Fixation of Tibial Shaft and
 Distal Radius Fractures in Adults (1998) by N Calvert, P Triffit, S Johnstone 
 and RG Richards. Series Editor: Nick Payne. 
 
£10.00 
98/04 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy and Autologous Stem Cell Transplantation in the Treatment 
of Hodgkin’s Disease and Non-Hodgkin’s Lymphoma (1998) by S Beard, P 
Lorigan, A Simms and F Sampson. Series Editor: Nick Payne. 
 
 
£10.00 
98/05 Working Group on Acute Purchasing: Angiotensin-Converting Enzyme 
(ACE) Inhibitors in Heart Failure: Reducing Mortality and Costs to the NHS 
(1998) by N Calvert, J Cornell and C Singleton. Series Editor: Nick Payne. 
 
 
£10.00 
98/06 Working Group on Acute Purchasing The Use Of Ultrasound (Viability) 
Scans In Early Pregnancy Bleeding (1998) by N Calvert, C Singleton and P 
Tromans. Series Editor: Nick Payne. 
 
£10.00 
98/08 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy with Autologous Stem Cell / Bone Marrow Transplantation 
in the Treatment of Multiple Myeloma (1998) by S Beard, F Sampson, E 
Vandenberghe and F Scott. Series Editor: Nick Payne. 
 
£10.00 
98/10 Working Group on Acute Purchasing: Supplementary Document: The Use 
of Paclitaxel in the First Line Treatment of Ovarian Cancer (1998) by S 
Beard, R Coleman, J Radford and J Tidy. Series Editor: Nick Payne. 
 
£10.00 
98/11 Working Group on Acute Purchasing: The Use of Fluoridated School Milk 
in the Prevention of Dental Caries (1998) by N Calvert and N Thomas. 
Series Editor: Nick Payne. 
 
£10.00 
99/01 Working Group on Acute Purchasing: The Role of Antileukotrienes in the 
Treatment of Chronic Asthma (1999) by M Stevenson, R Richards and S 
Beard. Series Editor: Nick Payne. 
 
£15.00 
99/02 Working Group on Acute Purchasing: Partial Hepatectomy for Liver 
Metastases (1999) by S Beard, M Holmes, A Majeed and C Price. Series 
Editor: Nick Payne. 
 
£15.00 
99/03 Working Group on Acute Purchasing: A Review of the Use of Propen-
tofylline in the Treatment of Dementia (1999) by J Chilcott, K Perrett, P 
Golightly, J Sykes and M Whittingham. Series Editor: Nick Payne. 
£15.00 
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99/04 Working Group on Acute Purchasing: The Use of Routine Anti-D 
prophylaxis Antenatally to Rhesus Negative Women (1999) by M Allaby, K 
Forman, S Touch and J Chilcott. Series Editor: Nick Payne. 
 
£15.00 
99/05 Working Group on Acute Purchasing: Magnetic Resonance Imaging (MRI) 
in the Management of Knee Disorders (1999) by SM Beard, I Perez , S 
Touch and D Bickerstaff. Series Editor: Nick Payne. 
 
£15.00 
99/06 Working Group on Acute Purchasing: The Effectiveness of Surgery in the 
Management of Epilepsy (1999) by J Chilcott, S Howell, A Kemeny, C 
Rittey and Richards C. Series Editor: Nick Payne.  
 
£15.00 
99/07 Working Group on Acute Purchasing: Tacrolimus and Mycophenolate 
Mofetil as Maintenance Immunosuppressants Following Renal 
Transplantation (1999) by J Chilcott, M Corcoran, KM Rigg and RP 
Burden. Series Editor: Nick Payne. 
 
£15.00 
99/08 Working Group on Acute Purchasing: The Use of Endovascular Stents for 
Abdominal Aortic Aneurysm (1999) by NW Calvert, M Lloyd Jones, S 
Thomas, RG Richards and JN Payne. Series Editor: Nick Payne. 
 
£15.00 
00/01 Working Group on Acute Purchasing: The Effectiveness of Intrathecal 
Baclofen in the Management of Patients with Severe Spasticity (2000) by 
FC Sampson, SH Touch, A Hayward, G Evans, R Morton, D Playford, M 
Vloeburghs, A Collett, and P Critchley. Series Editor: Nick Payne. 
 
£15.00 
00/02 Working Group on Acute Purchasing: Summary of the Current Evidence of 
Comparative Effectiveness for SSRIs and TCAs in the First Line Treatment 
of Depression in Primary Care (2000) by S Beard, C McGarrity and S 
Touch. Series Editor: Nick Payne. 
 
£15.00 
00/03 Working Group on Acute Purchasing: The Use of Hyperbaric Oxygen in the 
Management of Patients with Oral Cancer (2000) by S Ward, N Thomas, C 
Mander and I Brook. Series Editor: Nick Payne. 
 
£15.00 
 
Discussion Papers 
 
 
  
No. 1. Patients with Minor Injuries: A Literature Review of Options for their   £7.00 
 Treatment Outside Major Accident and Emergency Departments   
 or Occupational Health Settings (1994) by S Read.      
  
96/01  Working Group on Acute Purchasing: The Role of Beta Interferon   £7.50 
 in the Treatment of Multiple Sclerosis (1996) by RG Richards,   
 CJ McCabe, NJ Cooper, SF Paisley, A Brennan and RL Akehurst.   
  
96/02 The Mid-level Practitioner: A Review of the Literature on Nurse Practitioner  £10.00 
 and Physician Assistant Programmes (1996) by P Watson, N Hendey,   
 R Dingwall, E Spencer and P Wilson.    
  
96/03 Evaluation of two Pharmaceutical Care Programmes for People with  £10.00 
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 Mental Health Problems Living in the Community (1996) by A Aldridge,    
 R Dingwall and P Watson.         
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97/01 Working Group on Primary and Community Care Purchasing : Report of  £10.00 
  the Sub-Group on the promotion of Quality in Primary Care - Effective  
 Purchasing of Primary and Community Health Care: Promotion of Quality   
 in the Provision of Primary Care (1997) by S Jennings and M Pringle.  
  
97/02 Working Group on Primary and Community Care Purchasing : Report of £10.00 
  the Sub-Group on Information Needs for Health Needs Assessment and   
 Resource Allocation (1997) by T Baxter, A Howe, C Kenny, D Meechan,   
 M Pringle, P Redgrave, J Robinson and A Sims.  
  
98/01 Working Group on Primary and Community Care Purchasing : Hospital at 
Home - Lessons from Trent (1998) by I Perez, A Wilson, A Sims and R 
Harper. 
£10.00 
 
00/01 Genetic Counselling: A Review of the Literature (2000) by A Pilnick, R 
Dingwall, E Spencer and R Finn. 
 
£15.00 
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